公开(公告)号：US20200299392A1

公开(公告)日：2020-09-24

申请号：US16808910

申请日：2020-03-04

Applicant: Five Prime Therapeutics, Inc. ,  Bristol-Myers Squibb Company

Inventor： Brian Wong ,  Julie Hambleton ,  Robert Sikorski ,  Emma Masteller ,  Kevin Hestir ,  David Bellovin ,  Katherine E. Lewis

IPC: C07K16/28 ,  C07K16/30

Abstract: Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with PD-1/PD-L1 inhibitors are provided.

公开(公告)号：US10537611B2

公开(公告)日：2020-01-21

申请号：US16003590

申请日：2018-06-08

Applicant: Five Prime Therapeutics, Inc.

Inventor： Thomas Harding ,  Servando Palencia ,  Li Long ,  Kevin Hestir

IPC: A61K38/17 ,  A61K45/06 ,  A61K39/395 ,  A61K45/00 ,  C07K14/71 ,  C12Q1/6813 ,  C12Q1/686 ,  G01N33/50

Abstract: Methods of treating cancers comprising FGFR1 gene amplification are provided. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule in combination with at least one additional therapeutic agent.

公开(公告)号：US20190194288A1

公开(公告)日：2019-06-27

申请号：US16295978

申请日：2019-03-07

Applicant: Five Prime Therapeutics, Inc.

Inventor： Thomas BRENNAN ,  David BELLOVIN ,  David BUSHA ,  Barbara SENNINO

IPC: C07K14/705 ,  A61K39/395 ,  A61K38/17 ,  C07K16/00 ,  A61K45/06 ,  C07K16/28

CPC classification number: C07K14/70532 ,  A61K38/00 ,  A61K38/1774 ,  A61K39/39558 ,  A61K45/06 ,  C07K16/00 ,  C07K16/2803 ,  C07K2317/41 ,  C07K2319/03 ,  C07K2319/30

Abstract: This application relates to CD80 (B7-1) extracellular domain (ECD) polypeptides and CD80-ECD fusion molecules and their use in treatment of cancer, both alone and in combination with other therapeutic agents, such as immune stimulating agents such as PD-1/PD-L1 inhibitors.

公开(公告)号：US10273281B2

公开(公告)日：2019-04-30

申请号：US15340238

申请日：2016-11-01

Applicant: Five Prime Therapeutics, Inc.

Inventor： Thomas Brennan ,  David Bellovin ,  David Busha ,  Barbara Sennino

IPC: C07K14/705 ,  A61K38/17 ,  A61K39/395 ,  A61K45/06 ,  C07K16/00 ,  C07K16/28 ,  A61K38/00

Abstract: This application relates to CD80 (B7-1) extracellular domain (ECD) polypeptides and CD80-ECD fusion molecules and their use in treatment of cancer, both alone and in combination with other therapeutic agents, such as immune stimulating agents such as PD-1/PD-L1 inhibitors.

公开(公告)号：US20190000920A1

公开(公告)日：2019-01-03

申请号：US16003590

申请日：2018-06-08

Applicant: Five Prime Therapeutics, Inc.

Inventor： Thomas Harding ,  Servando Palencia ,  Li Long ,  Kevin Hestir

IPC: A61K38/17 ,  G01N33/50 ,  C12Q1/6813 ,  C12Q1/686 ,  C07K14/71 ,  A61K39/395 ,  A61K45/06 ,  A61K45/00

Abstract: Methods of treating cancers comprising FGFR1 gene amplification are provided. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule in combination with at least one additional therapeutic agent.

公开(公告)号：US20180016555A1

公开(公告)日：2018-01-18

申请号：US15520998

申请日：2015-10-21

Applicant: Five Prime Therapeutics, Inc.

Inventor： Luis Borges ,  Nathan Sallee ,  Charles Kaplan ,  Arthur Brace ,  W. Michael Kavanaugh ,  Brian Wong ,  David Bellovin ,  Thomas Brennan ,  Artur Karasyov

IPC: C12N5/0783 ,  C07K16/28 ,  G01N33/50

CPC classification number: C12N5/0636 ,  C07K16/2803 ,  C07K16/2896 ,  C07K2317/76 ,  C07K2319/30 ,  C12N2501/599 ,  G01N33/505

Abstract: Methods of identifying and using SLAMF1 antagonists are provided.

公开(公告)号：US20160326254A1

公开(公告)日：2016-11-10

申请号：US15154822

申请日：2016-05-13

Applicant: Five Prime Therapeutics, Inc.

Inventor： Brian Wong ,  Emma Masteller ,  Kris Reedquist

IPC: C07K16/28 ,  A61K39/395

CPC classification number: C07K16/2866 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/92 ,  G01N2333/52 ,  G01N2333/96494 ,  G01N2800/52

Abstract: Methods of reducing cytokine levels and methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided. Such methods include, but are not limited to, methods of treating inflammatory conditions, such as rheumatoid arthritis.

Abstract translation: 提供了降低细胞因子水平的方法和用克隆集落刺激因子1受体（CSF1R）的抗体治疗病症的方法。 这些方法包括但不限于治疗炎症性疾病如风湿性关节炎的方法。

公开(公告)号：US20160067307A1

公开(公告)日：2016-03-10

申请号：US14785691

申请日：2014-04-30

Applicant: FIVE PRIME THERAPEUTICS, INC. ,  GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED

Inventor： Julie Hambleton ,  Maureen R. Bleam ,  Maurice P. DeYoung ,  Geraldine Ferron-Brady ,  Rakesh Kumar ,  Lone Ottesen

IPC: A61K38/17

CPC classification number: A61K38/179

Abstract: Methods of treating cancers comprising FGFR1 gene amplification, FGFR1 overexpression, FGFR3 overexpression, FGFR3 amplification, FGF2 overexpression, and/or FGF2 gene amplification are provided. In some embodiments, the methods comprise administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule. In some embodiments, the methods comprise administering a FGFR1 ECD and/or an FGFR1 ECD fusion molecule in combination with at least one additional therapeutic agent. In some embodiments, methods of treating cancers comprising administering a FGFR1 ECD and/or an FGFR1 ECD fusion molecule in combination with at least one chemotherapeutic agent are provided.

Abstract translation: 提供了治疗包括FGFR1基因扩增，FGFR1过表达，FGFR3过表达，FGFR3扩增，FGF2过表达和/或FGF2基因扩增的癌症的方法。 在一些实施方案中，所述方法包括施用成纤维细胞生长因子受体1（FGFR1）细胞外结构域（ECD）和/或FGFR1 ECD融合分子。 在一些实施方案中，所述方法包括与至少一种另外的治疗剂组合施用FGFR1 ECD和/或FGFR1 ECD融合分子。 在一些实施方案中，提供了治疗癌症的方法，包括与至少一种化学治疗剂组合施用FGFR1 ECD和/或FGFR1 ECD融合分子。

公开(公告)号：US20160046719A1

公开(公告)日：2016-02-18

申请号：US14924568

申请日：2015-10-27

Applicant: Five Prime Therapeutics, Inc.

Inventor： Justin Wong ,  Maximiliano Vasquez

IPC: C07K16/28 ,  A61K45/06 ,  A61K39/395

CPC classification number: C07K16/2866 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  C12N15/11 ,  C12N15/63

Abstract: Antibodies that bind CSF1R are provided. Antibody heavy chains and light chains that are capable of forming antibodies that bind CSF1R are also provided. Polynucleotides encoding antibodies to CSF1R are provided. Polynucleotides encoding antibody heavy chains and lights chains are also provided. Methods of treatment using antibodies to CSF1R are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis, bone loss, and multiple sclerosis.

Abstract translation: 提供了结合CSF1R的抗体。 还提供能够形成结合CSF1R的抗体的抗体重链和轻链。 提供编码CSF1R抗体的多核苷酸。 还提供了编码抗体重链和灯链的多核苷酸。 提供使用抗CSF1R抗体的方法。 这些方法包括但不限于治疗类风湿性关节炎，骨丢失和多发性硬化症的方法。

公开(公告)号：US20160017024A1

公开(公告)日：2016-01-21

申请号：US14773329

申请日：2014-03-07

Applicant: FIVE PRIME THERAPEUTICS, INC.

Inventor： Lewis T. Williams ,  Hongbing Zhang ,  Kevin Hester ,  Thomas Harding

IPC: C07K16/18 ,  C07K16/40 ,  G01N33/573 ,  A61K45/06 ,  A61K39/395 ,  A61K38/17 ,  C07K16/00 ,  A61K38/45

CPC classification number: C07K16/18 ,  A61K38/1703 ,  A61K38/45 ,  A61K39/3955 ,  A61K45/06 ,  C07K16/00 ,  C07K16/40 ,  C07K2319/30 ,  C12Y207/10001 ,  G01N33/573 ,  G01N2333/4706 ,  G01N2333/912 ,  G01N2440/14 ,  G01N2500/02 ,  G01N2500/04 ,  G01N2500/10

Abstract: Methods of identifying and using FAM150A agents, FAM150B agents, and FAM150 antagonists are provided. Methods of identifying and using LTK agonists (including LTK agonist antibodies, FAM150A agents, and FAM150B agents) and FAM150 antagonists are provided. Such methods include, but are not limited to, methods of treating cancer, methods of treating immune disorders such as autoimmune diseases, and methods of treating neurodegenerative diseases.

Abstract translation: 提供了鉴定和使用FAM150A试剂，FAM150B试剂和FAM150拮抗剂的方法。 提供鉴定和使用LTK激动剂（包括LTK激动剂抗体，FAM150A试剂和FAM150B试剂）和FAM150拮抗剂的方法。 这些方法包括但不限于治疗癌症的方法，治疗免疫疾病如自身免疫性疾病的方法和治疗神经变性疾病的方法。